Novavax

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

during the visit of the Governor of Maryland Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus (RSV), avian flu, shingles, Clostridioides difficile, and malaria.

Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.

during the visit of the Governor of Maryland Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus (RSV), avian flu, shingles, Clostridioides difficile, and malaria.

Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.

Finance and external sponsorships

Novavax is funded by a mix of private and public investment. In 2015, Novavax received a US$89 million research grant from the Bill and Melinda Gates Foundation to support the development of a vaccine against RSV for infants via maternal immunization.

In May 2020, Novavax received from the Coalition for Epidemic Preparedness Innovations to fund early-stage evaluation in healthy adults of the company's COVID-19 vaccine candidate and to develop resources in preparation for large-scale manufacturing, if the vaccine proves successful. CEPI had already invested $4 million in March.

On 7 July 2020, during the Donald Trump administration, the company was awarded a loan from the United States government from Operation Warp Speed program to cover the testing, commercialization and production of a potential coronavirus vaccine in the United States, with a goal of delivering 100 million doses by January 2021. Novavax announced a $1.2 billion partnership with Sanofi in October 2024, allowing Sanofi to use Novavax’s Matrix-M adjuvant for other products.

The partnership allows Novavax to develop its own Covid/influenza combination vaccine, with the rest of their pipeline shifting to preclinical. Novavax scaled back operations by about $1 billion from 2022 - 2024, with less focus on research and development. In December 2024, Novavax sold its Czech manufacturing facility to Novo Nordisk for $200 million.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1365613826 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

28 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.